Search
Diazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A190372] When administered intravenously, diazoxide can be used to treat hypertensive emergencies;[L44622] however, this specific form of diazoxide is no longer available in the US. … [A255647,L44612] In March 2025, an extended-release formulation of diazoxide choline was approved by the FDA for the treatment of hyperphagia in patients with Prader-Willi syndrome, becoming the first
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingSynonyms: 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxideFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. … [A190516] The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: Tiacumicin BArdeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnIts molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000. … Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.
Suprofen
go.drugbank.com/drugs/DB00870ApprovedWithdrawnAn ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
Synonyms: 2-(4-(2-Thenoyl)phenyl)propionsäure, (±)-2-(p-(2-thenoyl)phenyl)propionic acidCategories: Non COX-2 selective NSAIDS, Cytochrome P-450 SubstratesRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexRibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalAdditionally, including ribavirin in the regimen can increase the risk of anemia. … In HCV genotye 1/2/3/4/5/6 patients, ribavirin can be used in combination therapy involving [DB09102] and [DB08934], Eplusa ([DB08934], [DB11613]), Harvoni ([DB08934], [DB09027]), [DB06290] and [DB08934
Synonyms: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamideCategories: Treatments for Hepatitis CBeclomethasone dipropionate
go.drugbank.com/drugs/DB00394ApprovedInvestigationalBeclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. … [L6871] It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP)[A179839] which acts on the glucocorticoid receptor to mediates its therapeutic action.
Synonyms: (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione, 9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionateInternational brands: Clenil-AAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was granted FDA approval on 24 May 2019. … [A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational[A263066] An Denosumab biosimilar, Jubbonti, was approved for Health Canada in February 2024.[L52083]. … ; Both biosimilars also received marketing authorization in the EU in May 2024.
Products: PROLIA®, XGEVA® 120 MG/1.7 MLSetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[L24474] It is an agonist of the melanocortin 4 receptor. … [L24429] On May 4, 2023, it was approved by Health Canada.[L46327]
Categories: Melanocortin 4 Receptor Agonist, Melanocortin 4 Receptor Agonists